MAGE-A3 Immunotherapeutic as Adjuvant Therapy for MAGE-A3–Positive Stage III Melanoma


Key Points

  • The MAGE-A3 immunotherapeutic improved disease-free survival vs placebo.
  • Development of the agent to treat melanoma has been stopped.

In the phase III DERMA trial reported in The Lancet Oncology, Dreno et al found that an adjuvant MAGE-A3 immunotherapeutic provided no benefit vs placebo in patients with resected MAGE-A3–positive stage IIIB or IIIC melanoma. Development of the agent for use in melanoma has been stopped.

The MAGE-A3 cancer-testis tumor antigen is expressed in the majority of melanomas. The MAGE-A3 immunotherapeutic consists of a recombinant MAGE-A3 protein given with the immunostimulant AS15 and was designed to enhance humoral and cell-mediated immune responses against MAGE-A3–expressing cells.

Study Details

In the double-blind trial, 1,391 patients with stage IIIB or IIIC disease from 263 sites in 31 countries were randomized 2:1 between December 2008 and September 2011 to receive MAGE-A3 immunotherapeutic (n = 921) or placebo (n = 470). Patients in the MAGE-A3 group received up to 13 intramuscular injections over a 27-month period, consisting of 5 doses at 3-week intervals followed by 8 doses at 12-week intervals.

The co-primary outcomes were disease-free survival in the overall population and in patients with a potentially predictive gene signature (GS-positive).

At final analysis, median follow-up was 28 months. Median disease-free survival was 11.0 months in the MAGE-A3 group vs 11.2 months in the placebo group (hazard ratio [HR] = 1.01, P = .86). In the GS-positive population (316 MAGE-A3 patients, 116 placebo patients), median disease-free survival was 9.9 months vs 11.6 months (HR = 1.11, P = .48).

Adverse Events

Within the first 31 days of treatment, grade ≥ 3 adverse events occurred in 14% of the MAGE-A3 group and 12% of the placebo group (considered treatment-related in 4% vs 1%), with the most common being neoplasms (4% vs 4%); general disorders and administration site conditions (3% vs < 1%); and infections and infestations (2% vs 2%). Serious adverse events were reported in 14% of both groups. No treatment-related deaths were reported.

The investigators concluded, “An antigen-specific immunotherapeutic alone was not efficacious in this clinical setting. Based on these findings, development of the MAGE-A3 immunotherapeutic for use in melanoma has been stopped.”

The study was funded by GlaxoSmithKline Biologicals SA.

Fernando Ulloa-Montoya, PhD, of GlaxoSmithKline, Rixensart, Belgium, is the corresponding author for The Lancet Oncology article.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.